Considering CSL shares? Broker says this other ASX 200 healthcare share has 30% upside

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

There are a number of S&P/ASX 200 Index (ASX: XJO) healthcare shares that we can pick from. CSL Limited (ASX: CSL) shares may be one of the most recognised companies on the ASX. But, Sonic Healthcare Limited (ASX: SHL) shares could be an even better choice.

Sonic Healthcare is not exactly a small-cap ASX share. According to the ASX, it has a market capitalisation of close to $16 billion.

The ASX 200 healthcare share describes itself as an “internationally renowned healthcare provider with specialist operations in laboratory medicine and pathology, radiology, general practice medicine and corporate medical services”.

Its main source of earnings comes from pathology. Sonic employs more than 1,800 pathologists and radiologists, and more than 14,000 medical scientists, radiographers, sonographers, technicians, and nurses.

Sonic Healthcare has operations in countries including Australia, New Zealand, the USA, Germany, and other European countries.

Expert sees an opportunity with this ASX 200 healthcare share

According to reporting by the Australian Financial Review, the broker RBC Capital Markets has increased its price target on Sonic shares to $43, up from $42, thanks to a positive trading update. That implies a possible rise of around more than 30% over the next 12 months.

That trading update showed two different sets of comparisons, which enabled investors to see how the company was trading.

Total revenue for the four months to October 2022 was $2.73 billion. This was down 11.7% year over year, but up 20.9% compared to the four months to October 2019 (pre-COVID times).

COVID testing didn’t exist in October 2019, but in the four months to October 2022, Sonic Healthcare generated $280 million of COVID testing revenue. That’s despite lockdowns being a thing of the past in the countries that it operates in. However, COVID testing revenue was 64.8% lower than in the four months to October 2021.

Sonic’s base business revenue was $2.45 billion in the four months to October 2022. This was a 6.7% increase year over year and an 8.5% increase compared to the four months to October 2019.

The numbers were more pronounced with operating profit, which Sonic explained was due to the fact that COVID testing – which saw a year-over-year decrease – utilises existing Sonic infrastructure, meaning it generated a higher profit on that revenue. Lower COVID testing meant considerably lower profitably. Fee revenue for each COVID test has also reduced.

Earnings before interest, tax, depreciation and amortisation (EBITDA) for the four months to October 2022 came to $621 million. This was a 37.3% decrease year over year, but a 32.7% increase compared to the four months to October 2019.

Expert commentary

The broker RBC Capital Markets said, according to the AFR:

Sonic Healthcare’s trading update for the 4 months to October 22 revealed the base business grew 6.7% (performing better than we expected) and is 7.8% higher than pre-pandemic levels.

However, the company’s margins compressed more than we anticipated. While we have had to cut our FY23 forecasts, we now expect Sonic Healthcare’s earnings to inflect in FY24 and those investors who have been waiting for positive earnings momentum can begin to re-evaluate the stock again.

Sonic Healthcare share price snapshot

While the ASX 200 healthcare share has dropped around 5% in the last week, it’s up approximately 3% over the past month.

The post Considering CSL shares? Broker says this other ASX 200 healthcare share has 30% upside appeared first on The Motley Fool Australia.

FREE Beginners Investing Guide

Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…

For over a decade, we’ve been helping everyday Aussies get started on their journey.

And to help even more people cut through some of the confusion “experts” seem to want to perpetuate – we’ve created a brand-new “how to” guide.

Yes, Claim my FREE copy!
*Returns as of November 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/nZHksVJ

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *